Deutsche Tageszeitung - Man who let snakes bite him 200 times spurs new antivenom hope

Man who let snakes bite him 200 times spurs new antivenom hope


Man who let snakes bite him 200 times spurs new antivenom hope
Man who let snakes bite him 200 times spurs new antivenom hope / Photo: © CENTIVAX/AFP

Tim Friede was feeling particularly down on the day after the September 11 attacks, so he went to his basement and let two of the world's deadliest snakes bite him.

Change text size:

Four days later, he woke up from a coma.

"I know what it feels like to die from snakebite," Friede told AFP via video call from his home in the small US town of Two Rivers, Wisconsin.

This experience might put most people off snakes entirely, but Friede simply vowed to be more careful next time.

From 2000 to 2018, he allowed himself to be bitten by snakes more than 200 times. He also injected himself with their venom over 650 times.

Friede endured this pain because he wanted to achieve total immunity to venom, a practice called mithridatism which should not be tried at home.

After a couple of years, Friede started to believe he could be the basis for a better kind of antivenom. The former truck mechanic, who does not have a university degree, long struggled to be taken seriously by scientists.

But last month, a study published in the prestigious Cell journal showed that antibodies from his blood protect against a range of snake venom.

The researchers now hope Friede's hyper-immunity could even lead to the development of a universal antivenom.

This would fill a major need, because currently most antivenoms only cover one or a few of the world's 600 venomous snakes.

Up to 138,000 people are killed by snakebites a year, while 400,000 suffer amputations or other disabilities, according to the World Health Organization.

These figures are believed to be vastly underestimated because snakebite victims typically live in poorer, remote areas.

- 'Pain every time' -

Friede's first bite was from a harmless garter snake when he was five years old.

"I was afraid, I cried, I ran away," said Friede, now 57.

Then he started bringing snakes home and hiding them in pickle jars. His mother sought counselling, but his interest in snakes persisted.

Things escalated after Friede attended a class that taught him how to "milk" snakes for their venom.

How antivenom is made has changed little over the last 125 years.

Small doses of snake venom are injected into animals such as horses, which produce antibodies that can be extracted and used as antivenom.

However this antivenom usually only works for bites from that particular species of snake -- and it includes other antibodies from horse that can cause serious side-effects including anaphylactic shock.

"I thought, well, if they make antivenom in horses, why can't I just use myself as a primate?" Friede said.

He started working through the venom from all the deadly species he could get his hands on, such as cobras, taipans, black mambas and rattlesnakes.

"There is pain every time," he said.

- 'Proud' -

For years, the scientists he contacted to take advantage of his immunity refused to bite.

Then in 2017, immunologist Jacob Glanville, who previously worked on universal vaccines, turned his attention towards antivenom.

Glanville told AFP he had been looking for "a clumsy snake researcher who'd been bit accidentally a couple times," when he came across a video of Friede taking brutal back-to-back snake bites.

When they first spoke, Glanville said he told Friede: "I know this is awkward, but I would love to get my hands on some of your blood."

"I've been waiting for this call for a long time," came the response, Glanville said.

The antivenom described in the Cell paper includes two antibodies from Friede's blood, as well as a drug called varespladib.

It offered mice full protection against 13 of the 19 snake species tested, and partial protection for the remaining six.

The researchers hope a future cocktail will cover far more snakes -- particularly vipers -- with further trials planned on dogs in Australia.

Timothy Jackson of the Australian Venom Research Unit praised the immunological research, but questioned whether a human needed to be involved, pointing to synthetically developed antibodies.

Glanville said the ultimate goal of his US-based firm Centivax was to develop a universal antivenom administered by something like an EpiPen, potentially produced in India to keep the costs down.

Friede said he was "proud" to have made a "small difference" in medical history.

Now working for Centivax, Friede stopped self-inflicting himself with venom in 2018 to save the firm from liability issues.

But he hopes to get bitten by snakes again in the future.

"I do miss it," he said.

(P.Hansen--DTZ)

Featured

Karbon-X Grows Global Reach with EU Allowances Trading Rollout

CALGARY, AB / ACCESS Newswire / June 18, 2025 / Karbon-X Corp. (OTCQX:KARX), a vertically integrated climate solutions company, has officially opened its EU trading accounts and commenced operations within the European Union Emissions Trading System (EU ETS). The expansion enables Karbon-X to provide direct access to EU Allowances (EUAs) for entities regulated under the EU ETS, further strengthening its compliance market capabilities.

With EuroPride, Lisbon courts LGBTQ travellers

Rainbow flags will fill Lisbon's streets on Saturday when the Portuguese capital hosts the annual EuroPride parade in support of LGBTQ rights which organisers hope will cement its standing as a gay-friendly destination.

Karbon-X and Directions Group Join Forces to Develop a Residential Solar Carbon Project Aligned with Alberta's TIER Program

CALGARY, AB / ACCESS Newswire / June 17, 2025 / Karbon-X Corp. (OTCQX:KARX), a vertically integrated climate solutions company, has entered into a strategic agreement with Directions Group Inc., a Canadian leader in clean energy sales and growth strategy. The partnership will focus on the development and implementation of a residential solar carbon project designed to generate offset credits eligible under Alberta's Technology Innovation and Emissions Reduction (TIER) regulation, one of Canada's most robust compliance carbon pricing systems.

Camino Announces High-Grade Channel Results of 7 Meters @ 4.3% Copper, 25.5 ppm Silver and 18 meters @ 1.57 % Copper and 11.35 ppm Silver at Los Chapitos in Peru

VANCOUVER, BC / ACCESS Newswire / June 17, 2025 / Camino Minerals Corporation (TSXV:COR)(OTC PINK:CAMZF) ("Camino" or the "Company") is pleased to announce high‐grade copper channel results from the Katty prospect located in the Diva Trend, one of several prospective targets at the Company's Los Chapitos Copper Project ("Los Chapitos" or the "Project") in Peru. A total of 12 excavated channels were completed at the prospect and all channels contained significant high-grade intercepts of copper with associated silver (Table 1). Los Chapitos is Camino's second copper project with partner Nittetsu Mining Co, Ltd. ("Nittetsu"), which can earn a 35% interest in Los Chapitos once it completes a total investment of CDN$10 Million (see news release dated June 14, 2023). Rio Tinto, a major copper producer, recently staked claims adjacent to Los Chapitos (see news release dated May 17, 2024). Camino is also advancing its mine development project, the Puquios Copper Project, with Nittetsu Mining in Chile (see news release dated April 17, 2025).

Change text size: